News

About 1 in every 50 West Virginia infants is exposed to the virus at birth.

Arthritis may soon be combated by rewired stem cells.

A series of successful tests excised HIV from the genomes of three animal models.

Cannabis gum may be on the horizon for patients with multiple sclerosis.

The guidelines call for a crackdown on chronic non-cancer pain prescriptions.

Treating systolic blood pressure of >120 mmHG reduces risk of acute decompensated heart failure.

Patients with colorectal cancer are at a higher risk for mood disorders.

Dads with depression could affect children's internal/external behavior.

Smokers found to have altered levels of MAIT than the general population.

Delaying LVAD therapy found not to impair survival, according to new study results.

Disposable commode pails reduced C. difficile infection rates by nearly a third after 1 year in 1 hospital studied.

Edavarone becomes first drug approved for disease since 1995.

On second try, the GOP has begun the process of repealing the ACA.

Abnormal HRV parameters may be associated with incident CHF in asymptomatic older adults.

Patients who received lifesaving kidney transplants from deceased donors infected with HCV were cured after undergoing antiviral drug therapy.

C. difficile infections are linked to medications regularly prescribed to children.

FDA to consider Xeljanz, the sole JAK inhibitor available in US, for new indication.

Ketamine evokes rapid and robust antidepressant effects, according to doctors

Approval includes a revised indication for initiation treatment.

Vascular death was 2.5 times more common with 0.3 mg ranibizumab than with sham.

High BMI in midlife may lead to higher risk of hospitalization for heart failure.

Wheezing from RV in the first 3 years of life leads to higher risk of asthma.

An argument for the ethical basis of using ketamine to treat depression.

Tablets are approved in several dose types

Researchers investigate school environment and exposure to microbes, fungi.

Glyceral phenylbutyrate now approved for people 2 months of age and older

A supplemental new drug application has been submitted to the US Food and Drug Administration (FDA) for 10-mg rivaroxaban as a treatment to reduce the risk of recurrent venous thromboembolism (VTE) after at least six months of standard anticoagulation therapy.

Factors include elevated carbohydrate antigen 125 and lactate dehydrogenase.

Abaloparatide reduces bone fractures, but raises tumor concerns.

A UK study aims to tackle poorly controlled asthma and misdiagnoses